|
|
Navidea Biopharmaceuticals, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: NAVB appeals CRG decision ; Supersedeas bond-- Net worth of Navidea end of 3rd quarter 2022, removing CRG estimated accrual of $3.3mm (principle plus interest), is an approximate negative $1.3mm edit: end of 3rd quarter 2022 assets
were $6.3mm and liabilities, after accrual of TX court ruling of $3.3mm
is $10.9mm, so net worth a negative $4.6mm. If you remove the Tx.
ruling net worth is still a negative $1.3mm |
||||||||||||
|
|
return to message board, top of board |
